The Blocking of Drug Resistance Channels by Selected Hydrophobic Statins in Chemoresistance Human Melanoma

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Drug resistance is a major challenge in cancer therapy, limiting treatment efficacy.
• P-glycoprotein (Pgp), an efflux pump, is a key mediator of multidrug resistance in various cancers, including melanoma.
• Statins, known for cholesterol-lowering, have emerged as potential modulators of drug transporters.

Purpose of the Study:

• To investigate the efficacy of hydrophobic statins in overcoming chemoresistance in melanoma.
• To evaluate the effect of statins on P-glycoprotein (ABCB1) activity and drug accumulation in resistant melanoma cells.
• To assess the impact of combining docetaxel with hydrophobic statins on tumor growth and toxicity in preclinical models.

Main Methods:

• Utilized chemoresistant human melanoma cell lines (A375P, WM239A, WM35) and a SCID mouse xenograft model.
• Administered docetaxel alone and in combination with hydrophobic statins.
• Assessed cell viability, necroptosis, DNA damage, drug absorption, and ABCB1 transporter activity.
• Monitored tumor size reduction and overall toxicity in the animal model.

Main Results:

• Hydrophobic statins significantly enhanced docetaxel accumulation in tumor cells by inhibiting the ABCB1 transporter.
• The combination therapy effectively reduced taxol-induced drug resistance.
• Significant tumor size reduction was observed in the animal model treated with docetaxel and statins.
• The structural similarity of statins was found to be of secondary importance for this effect.

Conclusions:

• Hydrophobic statins are effective in overcoming P-glycoprotein-mediated chemoresistance in melanoma.
• Combining statins with docetaxel increases drug efficacy and reduces toxicity.
• This approach presents a promising strategy to improve outcomes for cancer patients with drug-resistant tumors.